Fig. 7
Antitumour activity of combined JAK2 and KRASG12C inhibitors in vivo. A Tumour volume (mm3) of cell-derived tumours from H358 cells treated with indicated drugs (Sotorasib -Soto-: 10 mg/kg once daily; Fedratinib -Fedra-: 60 mg/kg twice daily). n = 10–12 tumours per group (Tukey’s multiple comparison test). B Representative images of tumours in A. C Waterfall plots of cell-derived tumours from H358 cells at the last day of experiment after being treated with the indicated drugs. D Tumour weight (g) of H358 cell-derived tumours of the tumours of A at end point (Dunnett’s multiple comparison test). E and F pH3 (E) and CC3 (F) quantification of H358 derived xenografts at end point (Dunnett’s multiple comparison test). G Tumour volume (mm3) of tumours derived from MiaPaca2 cells treated with indicated drugs (Soto: 10 mg/kg once daily; Fedra: 60 mg/kg twice daily). n = 12 tumours per group, (Tukey’s multiple comparison test). H Representative images of tumours in G. I Waterfall plots of cell-derived tumours from MiaPaca2 cells at the last day of experiment after being treated with the indicated drugs. J Tumour weight (g) of MiaPaca2 cell-derived tumours of the tumours from I (Dunnett’s multiple comparison test). K and L pH3 (E) and CC3 (F) quantification of MiaPaca2-derived xenografts at end point (Dunnett’s multiple comparison test)